Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.37 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PRNP | P04156 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8051296 | 0.81 | PARP1 (0.46) | PARP1KMT2AMEN1LMNADRD4 | |
| SCHEMBL16502119 | 0.81 | PARP1 (0.46) | PARP1KMT2AMEN1LMNADRD4 | |
| SCHEMBL7182478 | 0.77 | DRD2 (0.34) | PARP1DRD4DRD3DRD2 | |
| SCHEMBL4537910 | 0.77 | PARP1 (0.46) | PARP1KMT2AMEN1LMNATDP1 | |
| SCHEMBL29957158 | 0.77 | PARP1 (0.65) | PARP1KMT2AALDH1A1SMN1; SMN2AURKA | |
| SCHEMBL23123059 | 0.76 | PARP1 (0.50) | PARP1KMT2AMEN1BLMALDH1A1 | |
| SCHEMBL24241002 | 0.74 | MEN1 (0.37) | PARP1KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL1261706 | 0.74 | PARP1 (0.55) | PARP1KMT2AMEN1LMNADRD4 | |
| SCHEMBL15421060 | 0.73 | PARP1 (0.46) | PARP1DRD4DRD3DRD2BRD4 | |
| SCHEMBL4538554 | 0.73 | BRD4 (0.43) | PARP1KMT2ADRD4DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20260109670-A1 | METHOD FOR ARYL DEBROMINATION AND ACYLATION OF BROMINATED BENZO-FUSED NITROGEN HETEROCYCLE | Shanghai OuChem Bio-Technology Co., LTD (CN) | 2026-04-23 | — | — | US | disclosed |
| EP-3365339-B1 | NOVEL FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2025-07-16 | — | — | EP | disclosed |
| US-20250041319-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2025-02-06 | — | — | US | disclosed |
| CN-119143902-A | Method and apparatus for the localized polymerization of starting materials by bicolor photopolymerization | 效洛有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-119059958-A | Method for aryl debromination acylation of bromobenzazepine compounds | 上海沃凯生物技术有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-113993906-B | Method and device for the localized polymerization of starting materials by bicolor photopolymerization and method for the volumetric printing of shaped bodies | 效洛有限公司 | 2024-09-06 | — | — | CN | disclosed |
| US-12029744-B2 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | RIBOSCIENCE LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029744-B2 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | RIBOSCIENCE LLC (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024076155-A1 | NOVEL COMPOUND AS YEATS DOMAIN INHIBITOR | 노보렉스 주식회사 | 2024-04-11 | — | — | WO | disclosed |
| EP-2125805-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | Astex Therapeutics Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009093747-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-30 | — | — | WO | disclosed |
| EP-2078018-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008075109-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008051494-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
| EP-1480974-A1 | HETEROCYCLYLMETHYLPIPERIDINES AND -PIPERAZINES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003068771-A1 | HETEROCYCLYMETHYLPIPERIDINES AND -PIPERAZINES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003014116-A1 | PYRROLO[2.1-A]ISOQUINOLINE DERIVATIVES | BAYER CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
| US-5852008-A | Heteroatom substituted benzoyl derivatives that enhance synaptic response mediated by receptors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-12-22 | — | — | US | disclosed |
| CN-1010947-B | PROCESS FOR PREPN. OF PYRIDOPYRIMIDINES COMPOUNDS | BAYER AG (DE) | 1990-12-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109670-A1 | METHOD FOR ARYL DEBROMINATION AND ACYLATION OF BROMINATED BENZO-FUSED NITROGEN HETEROCYCLE | NAT1, AADAC, NAA15 | PARP1 1258/4885CYP2A6 493/4885IMPDH2 1285/4885 |
| US-20250041319-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, SMPD1 | PARP1 295/4885CYP2A6 936/4885IMPDH2 232/4885 |
| US-12029744-B2 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | ENPP1, ENPP3, SMPD1 | PARP1 298/4885CYP2A6 887/4885IMPDH2 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.